News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
41,727 Results
Type
Article (2701)
Company Profile (27)
Press Release (38998)
Multimedia
Podcasts (17)
Webinars (2)
Section
Business (16010)
Career Advice (78)
Deals (2150)
Drug Delivery (12)
Drug Development (4193)
Employer Resources (10)
FDA (453)
Job Trends (790)
News (20380)
Policy (1052)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (1)
2027 Genetown Digital (1)
2027 NextGen (2)
2027 Pharm Country Digital (1)
Academia (146)
ADA (4)
Allergies (8)
Alliances (3482)
ALS (9)
Alzheimer's disease (78)
Antibody-drug conjugate (ADC) (61)
Approvals (472)
Artificial intelligence (60)
ASCO (16)
Autoimmune disease (42)
Automation (6)
Bankruptcy (13)
Belgium (1)
Best Places to Work (476)
BIO (12)
Biologics (2)
BIOSECURE Act (2)
Biosimilars (27)
BioSpace Insights (13)
Biotechnology (17)
Bispecific (1)
Bladder cancer (11)
Brain cancer (9)
Breast cancer (64)
Cancer (487)
Cardiovascular disease (17)
Career advice (67)
Career pathing (1)
CAR-T (54)
CDC (2)
CDMO (8)
Celiac Disease (1)
Cell therapy (119)
Cervical cancer (7)
Clinical research (3674)
Collaboration (281)
Commercialization (2)
Company closure (4)
Compensation (160)
Complete response letters (1)
COVID-19 (187)
CRISPR (13)
CRO (1)
C-suite (208)
Cystic fibrosis (8)
Data (683)
Denatured (6)
Depression (12)
Dermatology (2)
Diabetes (25)
Diagnostics (518)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (60)
Drug pricing (10)
Duchenne muscular dystrophy (66)
Earnings (4784)
Editorial (6)
Employer branding (1)
Employer resources (8)
Events (6746)
Executive appointments (168)
FDA (674)
Fragile X (1)
Friedreich's ataxia (8)
Frontotemporal dementia (1)
Funding (250)
Gene editing (43)
Generative AI (3)
Gene therapy (83)
GLP-1 (83)
Government (164)
Guidances (25)
Healthcare (736)
Hematology (8)
HIV (4)
Huntington's disease (6)
IgA nephropathy (17)
Immunology and inflammation (45)
Immuno-oncology (24)
Indications (12)
Infectious disease (210)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (9)
Intellectual property (45)
Interviews (7)
IPO (1006)
IRA (7)
Job creations (291)
Job search strategy (62)
JPM (4)
Kidney cancer (13)
Kidney disease (7)
Labor market (13)
Layoffs (57)
Leadership (4)
Legal (213)
Licensing (8)
Liver cancer (8)
Longevity (7)
Lung cancer (47)
Lung diease (3)
Lymphoma (19)
Machine learning (5)
Management (4)
Manufacturing (97)
MASH (19)
Medical device (318)
Medtech (323)
Mergers & acquisitions (1280)
Metabolic disorders (109)
mRNA (19)
Multiple sclerosis (28)
Multispecific (1)
Neurodegenerative disease (46)
Neuropsychiatric disorders (14)
Neuroscience (229)
NextGen: Class of 2026 (354)
Non-profit (159)
Now hiring (17)
Obesity (54)
Opinion (21)
Ovarian cancer (31)
Pain (41)
Pancreatic cancer (29)
Parkinson's disease (17)
Partnered (4)
Patents (78)
Patient recruitment (66)
Patient selection (5)
Peanut (1)
People (6103)
Pharmaceutical (2)
Phase 1 (1575)
Phase 2 (1803)
Phase 3 (976)
Pipeline (932)
Policy (17)
Postmarket research (30)
Preclinical (677)
Press Release (3)
Prostate cancer (9)
Psychedelics (5)
Radiopharmaceuticals (23)
Rare diseases (113)
Real estate (425)
Recruiting (5)
Regenerative medicine (1)
Regulatory (1026)
Reports (7)
Research institute (149)
Resumes & cover letters (9)
Rett syndrome (5)
RNA editing (6)
RSV (3)
Schizophrenia (18)
Series A (63)
Series B (30)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (3)
Sponsored (1)
Startups (505)
Stomach cancer (3)
Supply chain (6)
Tariffs (2)
The Weekly (11)
Vaccines (76)
Venture capital (23)
Weight loss (30)
Women's health (30)
Women in leadership (1)
Worklife (1)
Date
Today (4)
Last 7 days (53)
Last 30 days (187)
Last 365 days (2439)
2026 (1937)
2025 (2440)
2024 (2591)
2023 (2858)
2022 (3755)
2021 (4042)
2020 (3463)
2019 (2057)
2018 (1548)
2017 (1793)
2016 (1619)
2015 (1831)
2014 (1367)
2013 (1185)
2012 (1392)
2011 (1328)
2010 (1174)
Location
Africa (43)
Alabama (3)
Arizona (21)
Asia (2041)
Australia (312)
California (2243)
Canada (344)
China (136)
Colorado (81)
Connecticut (24)
Delaware (17)
Europe (4187)
Florida (81)
Georgia (19)
Hawaii (2)
Idaho (3)
Illinois (34)
India (7)
Indiana (79)
Japan (25)
Kansas (16)
Kentucky (1)
Louisiana (2)
Maryland (82)
Massachusetts (822)
Michigan (15)
Minnesota (34)
Mississippi (1)
Missouri (6)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (187)
New York (124)
North Carolina (171)
Northern California (1161)
Ohio (66)
Oklahoma (2)
Oregon (7)
Pennsylvania (156)
Puerto Rico (1)
Rhode Island (4)
South America (40)
South Carolina (3)
Southern California (909)
Tennessee (6)
Texas (217)
United States (4515)
Utah (7)
Virginia (17)
Washington D.C. (4)
Washington State (120)
West Virginia (1)
Wisconsin (23)
41,727 Results for "xenetic biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
September 16, 2026
·
18 min read
Press Releases
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
October 15, 2026
·
9 min read
Press Releases
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 7, 2026
·
8 min read
Press Releases
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026
·
8 min read
Press Releases
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 23, 2026
·
1 min read
Press Releases
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026
·
7 min read
Press Releases
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026
·
7 min read
Press Releases
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 12, 2025
·
7 min read
Press Releases
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 14, 2025
·
8 min read
Press Releases
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 4, 2026
·
9 min read
1 of 4,173
Next
